Merck Lifts Annual Forecasts After Sales, Profit Beat Estimates
By Michael Erman (Reuters) -Merck & Co on Thursday posted better-than-expected sales and profit in the third quarter on a strong performance by its blockbuster cancer immunotherapy drug Keytruda and human papillomavirus vaccine Gardasil. Shares rose 2.6% in premarket trading as the drugmaker also raised its annual forecasts for sales and profit despite headwinds created…
